[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fzBsYHYyRu5lwTSWuP-CU9ju_wPitJ0ufratex7XoRWc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":42,"rows":49},"Centre de recherche du Centre hospitalier universitaire de Sherbrooke",[4],28,false,5,4,13480,2,18,[14,16,18,21,23,25,27,29],{"name":15,"count":11},"Neuroendocrine Tumors",{"name":17,"count":11},"COVID-19",{"name":19,"count":20},"Potentially Inappropriate Medication Use",1,{"name":22,"count":20},"Acute Myeloid Leukemia",{"name":24,"count":20},"Accidents, Traffic",{"name":26,"count":20},"Autoimmune Thyroid Disease",{"name":28,"count":20},"Congenital Hypothyroidism",{"name":30,"count":20},"Neuroblastoma",[32,37],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT05214820","68Ga-PSMA PET Imaging of Upper Metastatic Gastric Cancers to Determine Eligibility to Endoradiotherapy","2026-12-30","Radiopharmaceutical 68Ga-PSMA",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04559217","68Ga-DOTATATE Neuroblastoma Imaging Pilot","2027-12-15","Radiopharmaceutical 68Ga-DOTATATE",[43,44,45,46,47,48],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[50,73,95,126,144,162,190,215,241,267,295,313,339,367],{"intervention":41,"totalTrials":20,"cells":51},{"EARLY_PHASE1":52,"PHASE1":55,"PHASE2":57,"PHASE3":67,"PHASE4":69,"NA":71},{"trials":53,"activeCount":54},[],0,{"trials":56,"activeCount":54},[],{"trials":58,"activeCount":20,"soonestReadout":40},[59],{"nctId":38,"briefTitle":39,"status":60,"phases":61,"primaryCompletion":40,"completion":62,"start":63,"enrollment":64,"conditions":65,"interventions":66},"RECRUITING",[45],"2028-09-30","2021-12-06",20,[30],[41],{"trials":68,"activeCount":54},[],{"trials":70,"activeCount":54},[],{"trials":72,"activeCount":54},[],{"intervention":36,"totalTrials":20,"cells":74},{"EARLY_PHASE1":75,"PHASE1":77,"PHASE2":79,"PHASE3":89,"PHASE4":91,"NA":93},{"trials":76,"activeCount":54},[],{"trials":78,"activeCount":54},[],{"trials":80,"activeCount":20,"soonestReadout":35},[81],{"nctId":33,"briefTitle":34,"status":82,"phases":83,"primaryCompletion":35,"completion":84,"start":85,"enrollment":64,"conditions":86,"interventions":88},"ACTIVE_NOT_RECRUITING",[45],"2026-12-31","2022-01-17",[87],"Upper Digestive Tract Cancer",[36],{"trials":90,"activeCount":54},[],{"trials":92,"activeCount":54},[],{"trials":94,"activeCount":54},[],{"intervention":96,"totalTrials":20,"cells":97},"Higher doses of vasopressor therapy for a MAP of 75 mmHg",{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":124},{"trials":99,"activeCount":54},[],{"trials":101,"activeCount":54},[],{"trials":103,"activeCount":54},[],{"trials":105,"activeCount":54},[],{"trials":107,"activeCount":54},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":121},"NCT02744625","Physiologic Study of Cerebral Perfusion","COMPLETED",[47],"2017-03","2016-04",22,[117,118,119,120],"Cerebral Perfusion Pressure","Vasopressor Agents","Shock","Magnetic Resonance Imaging (MRI), Functional",[96,122,123],"Lower doses of vasopressor therapy for a MAP of 65 mmHg","Propofol for light sedation",{"trials":125,"activeCount":54},[],{"intervention":122,"totalTrials":20,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":136,"NA":142},{"trials":129,"activeCount":54},[],{"trials":131,"activeCount":54},[],{"trials":133,"activeCount":54},[],{"trials":135,"activeCount":54},[],{"trials":137,"activeCount":54},[138],{"nctId":109,"briefTitle":110,"status":111,"phases":139,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":140,"interventions":141},[47],[117,118,119,120],[96,122,123],{"trials":143,"activeCount":54},[],{"intervention":123,"totalTrials":20,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":154,"NA":160},{"trials":147,"activeCount":54},[],{"trials":149,"activeCount":54},[],{"trials":151,"activeCount":54},[],{"trials":153,"activeCount":54},[],{"trials":155,"activeCount":54},[156],{"nctId":109,"briefTitle":110,"status":111,"phases":157,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":158,"interventions":159},[47],[117,118,119,120],[96,122,123],{"trials":161,"activeCount":54},[],{"intervention":163,"totalTrials":20,"cells":164},"Deprescribing anticholinergic and sedative mediications",{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":173,"NA":188},{"trials":166,"activeCount":54},[],{"trials":168,"activeCount":54},[],{"trials":170,"activeCount":54},[],{"trials":172,"activeCount":54},[],{"trials":174,"activeCount":54},[175],{"nctId":176,"briefTitle":177,"status":178,"phases":179,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":187},"NCT05735379","Impact in Older Adults of Reducing Anticholinergic and Sedative Rx Burden on Physical Function Measured by Wearables","UNKNOWN",[47],"2025-06","2025-12","2023-03-23",182,[185,186],"Deprescribing Anticholinergic and Sedative Medications","Physical Function",[163],{"trials":189,"activeCount":54},[],{"intervention":191,"totalTrials":20,"cells":192},"Tranexamic Acid",{"EARLY_PHASE1":193,"PHASE1":195,"PHASE2":197,"PHASE3":199,"PHASE4":211,"NA":213},{"trials":194,"activeCount":54},[],{"trials":196,"activeCount":54},[],{"trials":198,"activeCount":54},[],{"trials":200,"activeCount":54},[201],{"nctId":202,"briefTitle":203,"status":178,"phases":204,"primaryCompletion":205,"completion":180,"start":206,"enrollment":207,"conditions":208,"interventions":210},"NCT02568124","Tranexamic Acid in Chronic Subdural Hematomas",[45,46],"2024-12","2015-11",130,[209],"Chronic Subdural Hematoma",[191],{"trials":212,"activeCount":54},[],{"trials":214,"activeCount":54},[],{"intervention":216,"totalTrials":20,"cells":217},"Radiosynoviorthesis",{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":222,"PHASE3":224,"PHASE4":237,"NA":239},{"trials":219,"activeCount":54},[],{"trials":221,"activeCount":54},[],{"trials":223,"activeCount":54},[],{"trials":225,"activeCount":54},[226],{"nctId":227,"briefTitle":228,"status":111,"phases":229,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":236},"NCT01615991","Multicentre Canadian Study to Measure the Safety and Efficacy of Radiosynoviorthesis",[46],"2017-12-31","2018-12-31","2012-05-31",300,[235],"Arthritis",[216],{"trials":238,"activeCount":54},[],{"trials":240,"activeCount":54},[],{"intervention":242,"totalTrials":20,"cells":243},"Natural products: Probiotics",{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":248,"PHASE3":261,"PHASE4":263,"NA":265},{"trials":245,"activeCount":54},[],{"trials":247,"activeCount":54},[],{"trials":249,"activeCount":54},[250],{"nctId":251,"briefTitle":252,"status":111,"phases":253,"primaryCompletion":254,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":260},"NCT04050189","Validation of the In-utero Transmission of Probiotics",[45],"2023-08-28","2023-11-28","2022-04-27",52,[259],"In Utero Drug Exposure",[242],{"trials":262,"activeCount":54},[],{"trials":264,"activeCount":54},[],{"trials":266,"activeCount":54},[],{"intervention":268,"totalTrials":20,"cells":269},"Loperamide Pill",{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":271,"activeCount":54},[],{"trials":273,"activeCount":54},[],{"trials":275,"activeCount":54},[276],{"nctId":277,"briefTitle":278,"status":111,"phases":279,"primaryCompletion":280,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":287},"NCT04823065","4FMFES-PET Imaging of Endometrial and Ovarian Cancers",[44,45],"2023-08-31","2024-04-30","2018-09-01",53,[285,286],"Endometrial Cancer","Ovarian Cancer",[268,288],"hyoscine-n-butylbromide",{"trials":290,"activeCount":54},[],{"trials":292,"activeCount":54},[],{"trials":294,"activeCount":54},[],{"intervention":288,"totalTrials":20,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":307,"PHASE4":309,"NA":311},{"trials":298,"activeCount":54},[],{"trials":300,"activeCount":54},[],{"trials":302,"activeCount":54},[303],{"nctId":277,"briefTitle":278,"status":111,"phases":304,"primaryCompletion":280,"completion":281,"start":282,"enrollment":283,"conditions":305,"interventions":306},[44,45],[285,286],[268,288],{"trials":308,"activeCount":54},[],{"trials":310,"activeCount":54},[],{"trials":312,"activeCount":54},[],{"intervention":314,"totalTrials":20,"cells":315},"oxaliplatin",{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":333,"PHASE4":335,"NA":337},{"trials":317,"activeCount":54},[],{"trials":319,"activeCount":54},[],{"trials":321,"activeCount":54},[322],{"nctId":323,"briefTitle":324,"status":178,"phases":325,"primaryCompletion":326,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":332},"NCT01019863","Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.",[45],"2010-10","2011-10","2008-10",50,[331],"Non-Hodgkin Lymphoma",[314],{"trials":334,"activeCount":54},[],{"trials":336,"activeCount":54},[],{"trials":338,"activeCount":54},[],{"intervention":340,"totalTrials":20,"cells":341},"Latanoprost, bimatoprost, travoprost",{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":348,"PHASE4":350,"NA":352},{"trials":343,"activeCount":54},[],{"trials":345,"activeCount":54},[],{"trials":347,"activeCount":54},[],{"trials":349,"activeCount":54},[],{"trials":351,"activeCount":54},[],{"trials":353,"activeCount":54},[354],{"nctId":355,"briefTitle":356,"status":178,"phases":357,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":365},"NCT01361841","Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma",[48],"2012-01","2013-01","2009-01",141,[363,364],"Ocular Hypertension","Primary Glaucoma",[340,366],"travoprost, latanoprost and bimatoprost",{"intervention":366,"totalTrials":20,"cells":368},{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":377,"NA":379},{"trials":370,"activeCount":54},[],{"trials":372,"activeCount":54},[],{"trials":374,"activeCount":54},[],{"trials":376,"activeCount":54},[],{"trials":378,"activeCount":54},[],{"trials":380,"activeCount":54},[381],{"nctId":355,"briefTitle":356,"status":178,"phases":382,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":383,"interventions":384},[48],[363,364],[340,366]]